Nuvation Bio (NUVB) – Research Analysts’ Recent Ratings Updates

A number of research firms have changed their ratings and price targets for Nuvation Bio (NYSE: NUVB):

• 1/21/2026 – Nuvation Bio had its price target raised by analysts at Royal Bank Of Canada from $9.00 to $12.00. They now have an “outperform” rating on the stock.
• 1/12/2026 – Nuvation Bio had its price target lowered by analysts at HC Wainwright from $18.00 to $17.00. They now have a “buy” rating on the stock.
• 1/7/2026 – Nuvation Bio is now covered by analysts at UBS Group AG. They set a “neutral” rating and a $10.00 price target on the stock.
• 1/7/2026 – Nuvation Bio is now covered by analysts at UBS Group AG. They set a “hold” rating and a $10.00 price target on the stock.
• 12/11/2025 – Nuvation Bio had its price target raised by analysts at HC Wainwright from $10.00 to $18.00. They now have a “buy” rating on the stock.
• 12/1/2025 – Nuvation Bio had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
• 11/24/2025 – Nuvation Bio was given a new $11.00 price target on by analysts at Truist Financial Corporation.
• 11/24/2025 – Nuvation Bio is now covered by analysts at Truist Financial Corporation. They set a “buy” rating and a $11.00 price target on the stock.

Insider Buying and Selling

In other Nuvation Bio news, insider Dongfang Liu sold 150,000 shares of the firm’s stock in a transaction that occurred on Monday, December 1st. The shares were sold at an average price of $7.82, for a total value of $1,173,000.00. Following the sale, the insider owned 18,000 shares in the company, valued at $140,760. This trade represents a 89.29% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider Gary Hattersley sold 100,000 shares of the business’s stock in a transaction on Monday, October 27th. The stock was sold at an average price of $5.02, for a total transaction of $502,000.00. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 320,000 shares of company stock valued at $2,050,800. 29.93% of the stock is currently owned by insiders.

Nuvation Bio is a clinical-stage biotechnology company dedicated to discovering and developing small-molecule therapies for patients with cancer. The company employs an integrated research and development platform that spans target identification, preclinical evaluation, process chemistry, and early-stage clinical trials. By centralizing these capabilities, Nuvation Bio aims to accelerate the translation of promising drug candidates from laboratory research to first-in-human studies.

The company’s pipeline comprises multiple oncology programs, with small-molecule kinase inhibitors and targeted agents in Phase 1 development for both hematologic malignancies and solid tumors.